Related Experiment Video
Updated: Aug 9, 2025
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
Roxadustat protect mice from DSS-induced colitis in vivo by up-regulation of TLR4
Zhenlan Feng1, Ying Cheng2, Yuedong Wang1
1School of Public Health and Management, Wenzhou Medical University, Zhejiang Province 325000, China; Department of Radiation Medicine, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Background:
The incidence of inflammatory bowel disease (IBD) is growing in the population. At present, the etiology of inflammatory bowel disease remains unclear, and there is no effective and low-toxic therapeutic drug. The role of the PHD-HIF pathway in relieving DSS-induced colitis is gradually being explored.
Methods:
Wild-type C57BL/6 mice were used as a model of DSS-induced colitis to explore the important role of Roxadustat in alleviating DSS-induced colitis. High-throughput RNA-Seq and qRT-PCR methods were used to screen and verify the key differential genes in the colon of mice between normal saline (NS) and Roxadustat groups.
Results:
Roxadustat could alleviate DSS-induced colitis. Compared with the mice in the NS group, TLR4 were significantly up-regulated in the Roxadustat group. TLR4 KO mice were used to verify the role of TLR4 in the alleviation of DSS-induced colitis by Roxadustat.
Conclusion:
Roxadustat has a repairing effect on DSS-induced colitis, and may alleviate DSS-induced colitis by targeting the TLR4 pathway and promote intestinal stem cell proliferation.
